- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Breast cancer
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Pertuzumab – March 2020
Pertuzumab: Solution for I.V. infusion 420 mg in 14 ml; Perjeta®
Last updated
17 July 2020